Tang Qi-dong, Wu Ping-sheng, Hou Yu-qing, Huang Zheng, Zhou Zhong-jiang, Guo Zhi-gang, Xiu Jian-cheng, Wang Yue-gang
Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2009 May;29(5):1004-7.
To investigate the changes in plasma matrix metalloproteinases-2 and -9 (MMP2 and MMP9, respectively) levels in patients with different types of coronary heart diseases (CHD), and assess the value of MMP2/MMP9 detection in predicting acute coronary syndrome (ACS).
According to the findings by coronary angiography and the clinical manifestations, 118 patients were divided in ACS group including 30 patients with unstable angina pectoris (UAP) and 19 with acute myocardial infarction (AMI) and non-ACS group including 23 patients with stable angina pectoris (SAP) and 21 with chronic total occlusion (CTO) of the coronary artery. Twenty-five individuals with normal coronary artery (NCA) served as the control group. Plasma levels of MMP9 and MMP2 were determined in these subjects using enzyme-linked immunosorbent assay (ELISA).
Both the ACS and non-ACS groups showed significantly higher MMP9 and MMP2 levels than the NCA group (P<0.05), and MMP2 and MMP9 levels were significantly higher in ACS group than in non-ACS group (P<0.05). Compared with the NCA group, the UAP, AMI and CTO subgroups showed obvious increases in plasma MMP2 and MMP9 levels (P<0.01). Significantly increased MMP9, but not MMP2 level was noted in AMI subgroup in comparison with SAP (P<0.01) and UAP subgroups (P<0.05); both MMP2 and MMP9 levels were elevated in CTO subgroup in comparison with those in SAP (P<0.001), UAP (P<0.01), and AMI subgroups (P<0.05).
Increased MMP2 and MMP9 levels in patients with CHD suggest the instability of the atherosclerotic plaque in correlation to the severity of ACS, and may serve as good indicators for the prediction of ACS and diagnosis of CTO of the coronary artery.
探讨不同类型冠心病（CHD）患者血浆基质金属蛋白酶-2和-9（分别为MMP2和MMP9）水平的变化，并评估MMP2/MMP9检测在预测急性冠脉综合征（ACS）中的价值。
根据冠状动脉造影结果及临床表现，将118例患者分为ACS组，包括30例不稳定型心绞痛（UAP）患者和19例急性心肌梗死（AMI）患者；非ACS组，包括23例稳定型心绞痛（SAP）患者和21例冠状动脉慢性完全闭塞（CTO）患者。25例冠状动脉正常（NCA）个体作为对照组。采用酶联免疫吸附测定（ELISA）法测定这些受试者血浆中MMP9和MMP2水平。
ACS组和非ACS组的MMP9和MMP2水平均显著高于NCA组（P<0.05），且ACS组的MMP2和MMP9水平显著高于非ACS组（P<0.05）。与NCA组相比，UAP、AMI和CTO亚组的血浆MMP2和MMP9水平明显升高（P<0.01）。与SAP亚组（P<0.01）和UAP亚组（P<0.05）相比，AMI亚组的MMP9水平显著升高，但MMP2水平无明显变化；与SAP亚组（P<0.001）、UAP亚组（P<0.01）和AMI亚组（P<0.05）相比，CTO亚组的MMP2和MMP9水平均升高。
冠心病患者MMP2和MMP9水平升高提示动脉粥样硬化斑块的不稳定性与ACS的严重程度相关，可能是预测ACS和诊断冠状动脉CTO的良好指标。
